<DOC>
	<DOC>NCT02164812</DOC>
	<brief_summary>The purpose of this study is to determine whether multiple doses of Efavirenz has an effect on the QTc interval (corrected by Fridericia) in CYP2B6 *1/*6 and *6/*6 healthy subjects.</brief_summary>
	<brief_title>Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects</brief_title>
	<detailed_description>CYP = Cytochrome p-450 Primary Purpose: Other: This is a Phase 1 clinical pharmacology thorough QT study being conducted as a post marketing requirement</detailed_description>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Healthy volunteers, ages 18 to 49 years old BMI 18 to 32 kg/m2 Women must not be pregnant or breastfeeding A personal history of clinically relevant cardiac disease, symptomatic or asymptomatic arrhythmias, presyncope or syncopal episodes, or additional risk factors for torsades de pointes (eg, heart failure) History of hypokalemia, personal history or family history of prolonged QT interval, or family history of sudden cardiac death at a young age Any of the following on 12lead electrocardiogram (ECG) prior to study drug administration: PR ≥210 msec, QRS ≥120 msec, QT ≥500 msec, QTcF ≥450 msec, HR &lt;45 bpm Second or third degree heart block prior to study drug Positive urine screen for drugs of abuse Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human Immunodeficiency Virus (HIV)1, 2 antibody Any of the following lab results outside of the ranges specified below prior to dosing: Alanine aminotransferase (ALT) &gt;upper limit of normal (ULN), aspartate aminotransferase (AST) &gt;ULN, Total bilirubin &gt;ULN, Direct bilirubin &gt;ULN, Creatinine &gt;ULN, Serum potassium &lt;lower limit of normal (LLN), Serum magnesium &lt;LLN History of allergy to Moxifloxacin, Efavirenz or related compounds</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>